



Press release

TxCell to participate in leading scientific conferences in Q2 2016

Valbonne, France, April 13, 2016 – TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T cells (Treg) to treat severe chronic inflammatory and autoimmune diseases, announces today that Stéphane Boissel, CEO of TxCell, and other senior management will chair and participate at roundtables, present at and attend, a number of leading scientific conferences during the second quarter of 2016.

TxCell will give updates about the development of its pipeline and technology platforms, including its second platform based on CAR-Tregs, ENTriA.

These conferences include:

- **PEGS Summit Boston**, April 25-29, Boston, United States
 - Arnaud Foussat, CSO of TxCell, will give a presentation entitled ‘Regulatory T Cells-Based Cellular Immunotherapy of Inflammation and Autoimmunity’ on April 26 at 11.20am local time.
- **World Stem Cells & Regenerative Medicines Congress 2016**, May 18-20, London, United Kingdom.
 - Stéphane Boissel, CEO of TxCell, will present TxCell’s strategy and latest developments in the ‘Biotech updates’ roundtables on May 19 at 11.25am local time.
 - Miguel Forte, COO of TxCell, will participate in the health economics panel entitled ‘Overcoming the reimbursement hurdles in cell and gene therapies globally’ on May 18 at 5pm local time.
- **ISCT (International Society for Cell Therapy) 2016 Annual Meeting**, May 25-28, Singapore
 - Two abstracts have been accepted as posters and will be presented by TxCell scientists.
 - Miguel Forte will co-chair a plenary session entitled ‘Opportunities and Challenges for Cell Therapy Commercialization in Asia’ on May 28 at 2.55pm local time.
- **North American Adoptive T Cell Therapy Congress**, June 28-30, Boston, United States
 - Arnaud Foussat will chair a workshop entitled ‘T-Cell based treatment of inflammation: antigen-specific Treg cells, TCR and CAR engineered Treg cells in transplantation, autoimmunity and chronic inflammatory diseases’ on June 28 at 9am local time.
 - Arnaud Foussat will also give a presentation entitled ‘Assessing Regulatory T-Cells as Therapy’ on June 30 at 12pm local time.

About TxCell – www.txcell.com

TxCell is a publicly listed biotechnology company that develops platforms for innovative, personalized T cell immunotherapies for the treatment of severe chronic inflammatory and autoimmune diseases with high unmet medical need. TxCell is the only clinical stage cellular therapy company dedicated to the science of regulatory T lymphocytes (Tregs). Tregs are a recently discovered T cell population for which anti-inflammatory properties have been demonstrated. Ovasave®, TxCell's lead product candidate, is currently in a phase IIb clinical trial in refractory Crohn's disease patients. Col-Treg, its second product candidate, for the treatment of autoimmune uveitis, is expected to enter in clinical studies in the near future. Based in Sophia-Antipolis, France, TxCell is listed on Euronext Paris and currently has 49 employees.

Contacts

TxCell

Caroline Courme
IR & Communication Director
Tel: +33(0) 4 97 21 83 00
caroline.courme@txcell.com

Image Box – Press relations

Neil Hunter / Michelle Boxall
Tel: +44(0) 20 8943 4685
neil.hunter@imageboxpr.co.uk
michelle.boxall@imageboxpr.co.uk

NewCap – Investor relations

Julien Perez / Pierre Laurent
Tel: +33 (0)1 44 71 98 52
txcell@newcap.eu

Forward-Looking Statements - TxCell

This press release contains certain forward-looking statements relating to the business of TxCell, which shall not be considered *per se* as historical facts, including TxCell's ability to develop, market, commercialize and achieve market acceptance for specific products, estimates for future performance and estimates regarding anticipated operating losses, future revenues, capital requirements, needs for additional financing. In addition, even if the actual results or development of TxCell are consistent with the forward-looking statements contained in this press release, those results or developments of TxCell may not be indicative of their in the future.

In some cases, you can identify forward-looking statements by words such as "could," "should," "may," "expects," "anticipates," "believes," "intends," "estimates," "aims," "targets," or similar words. Although the management of TxCell believes that these forward-looking statements are reasonably made, they are based largely on the current expectations of TxCell as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of TxCell could be affected by, among other things, uncertainties involved in the development of the Company's products, which may not succeed, or in the delivery of TxCell's products marketing authorizations by the relevant regulatory authorities and, in general, any factor that could affect TxCell capacity to commercialize the products it develops, as well as, any other risk and uncertainties developed or identified in any public documents filed by TxCell with the AMF, included those listed in chapter 4 "Risk factors" of the 2014 *document de référence* approved by the AMF on June 11, 2015 under number R.15-049 and in section 5.1 of its *actualisation* filed with the AMF on January 25, 2016 under number D.15-0402-A01. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Notwithstanding the compliance with article 223-1 of the General Regulation of the AMF (the information disclosed must be "accurate, precise and fairly presented"), TxCell is providing the information in these materials as of this press release, and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.